EDP Sciences logo
Subscriber Authentication Point
Rechercher
Menu
Accueil Tous les numéros Volume 42 / Numéro 6-7 (Juin-Juillet 2026) Med Sci (Paris), 42 6-7 (2026) 590-599 References
Open Access
Issue
Med Sci (Paris)
Volume 42, Number 6-7, Juin-Juillet 2026
Page(s) 590 - 599
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2026094
Published online 17 juillet 2026
  1. Noubiap JJ, Nansseu JR, Nyaga UF, et al. Worldwide trends in metabolic syndrome from 2000 to 2023: a systematic review and modelling analysis. Nat Commun 2025; 17: 573. [Google Scholar]
  2. Mocumbi AO. Cardiovascular health care in low- and middle-income countries. Circulation 2024; 149: 557–9. [Google Scholar]
  3. Ballena-Caicedo J, Zuzunaga-Montoya FE, Loayza-Castro JA, et al. Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis. J Health Popul Nutr 2025; 44: 308. [Google Scholar]
  4. Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J 2011; 162: 597–605. [Google Scholar]
  5. Taleb S. Inflammation in atherosclerosis. Arch Cardiovasc Dis 2016; 109: 708–15. [Google Scholar]
  6. Mouttoulingam N, Taleb S. Exploring tryptophan metabolism in cardiometabolic diseases. Trends Endocrinol Metab 2025; 36: 733–43. [Google Scholar]
  7. Gaboriau-Routhiau V, Cerf-Bensussan N. Microbiote intestinal et développement du système immunitaire. Med Sci (Paris) 2016; 32: 961–7. [Google Scholar]
  8. Boudaud M, Arnone D, Touly N, et al. Biodiversité du microbiote intestinal et alimentation moderne. Med Sci (Paris) 2026; 42: 65–70. [Google Scholar]
  9. Hays KE, Pfaffinger JM, Ryznar R. The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease. Gut Microbes 2024 ; 16 : 2393270. [Google Scholar]
  10. Zhang X, Kapoor D, Jeong S-J, et al. Identification of a leucine-mediated threshold effect governing macrophage mTOR signalling and cardiovascular risk. Nat Metab 2024; 6: 359–77. [Google Scholar]
  11. Bröer S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol Rev 2008; 88: 249–86. [Google Scholar]
  12. Andrukhov O, Hong JS-A, Andrukhova O, et al. Response of human periodontal ligament stem cells to IFN-γ and TLR-agonists. Sci Rep 2017; 7: 12856. [Google Scholar]
  13. Chajadine M, Laurans L, Radecke T, et al. Harnessing intestinal tryptophan catabolism to relieve atherosclerosis in mice. Nat Commun 2024; 15: 6390. [Google Scholar]
  14. Laurans L, Taleb S. IDO, une enzyme dangereuse pour l’obésité. Med Sci (Paris) 2018; 34: 660–1. [Google Scholar]
  15. Taleb S. Tryptophan dietary impacts gut barrier and metabolic diseases. Front Immunol 2019; 10: 2113. [Google Scholar]
  16. Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015; 161: 264–76. [Google Scholar]
  17. Lee J-H, Lee J. Indole as an intercellular signal in microbial communities. FEMS Microbiol Rev 2010; 34: 426–44. [Google Scholar]
  18. Schwarcz R, Bruno JP, Muchowski PJ, et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13: 465–77. [Google Scholar]
  19. Seo S-K, Kwon B. Immune regulation through tryptophan metabolism. Exp Mol Med 2023; 55: 1371–9. [Google Scholar]
  20. Wang Y, Liu H, McKenzie G, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med 2010; 16: 279–85. [Google Scholar]
  21. Gao J, Xu K, Liu H, et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol 2018; 8 : 13. [Google Scholar]
  22. Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011; 478: 197–203. [Google Scholar]
  23. Bansal T, Alaniz RC, Wood TK, et al. The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc Nat Acad Sci USA 2010; 107: 228–33. [Google Scholar]
  24. Williams BB, Van Benschoten AH, Cimermancic P, et al. discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe 2014; 16: 495–503. [Google Scholar]
  25. Agus A, Sokol H. Tryptophane et dérégulations métaboliques, un nouvel enjeu pour la santé. Med Sci (Paris) 2019; 35: 213–5. [Google Scholar]
  26. Homberg JR, Schubert D, Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 2010; 31: 60–5. [Google Scholar]
  27. Hung LY, Alves ND, Del Colle A, et al. Intestinal epithelial serotonin as a novel target for treating disorders of gut-brain interaction and mood. Gastroenterology 2025; 168: 754–68. [Google Scholar]
  28. Laurans L, Venteclef N, Haddad Y, et al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat Med 2018; 24: 1113–20. [Google Scholar]
  29. Sun P, Wang M, Liu Y-X, et al. High-fat diet-disturbed gut microbiota-colonocyte interactions contribute to dysregulating peripheral tryptophan-kynurenine metabolism. Microbiome 2023; 11: 154. [Google Scholar]
  30. Reigstad CS, Salmonson CE, III JFR, et al. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. The FASEB J 2015; 29: 1395–403. [Google Scholar]
  31. Favennec M, Hennart B, Caiazzo R, et al. The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation. Obesity 2015; 23: 2066–74. [Google Scholar]
  32. Huang T, Song J, Gao J, et al. Adipocyte-derived kynurenine promotes obesity and insulin resistance by activating the AhR/STAT3/IL-6 signaling. Nat Commun 2022; 13: 3489. [Google Scholar]
  33. Crane JD, Palanivel R, Mottillo EP, et al. Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat Med 2015; 21: 166–72. [Google Scholar]
  34. van Galen KA, ter Horst KW, Serlie MJ. Serotonin, food intake, and obesity. Obes Rev 2021; 22 : e13210. [Google Scholar]
  35. Taleb S. Are tryptophan metabolites new predictive biomarkers for CVD? Atherosclerosis 2023; 387: 117385. [Google Scholar]
  36. Metghalchi S, Ponnuswamy P, Simon T, et al. Indoleamine 2,3-dioxygenase fine-tunes immune homeostasis in atherosclerosis and colitis through repression of interleukin-10 production. Cell Metab 2015; 22: 460–71. [Google Scholar]
  37. Melhem NJ, Chajadine M, Gomez I, et al. Endothelial cell indoleamine 2, 3-dioxygenase 1 alters cardiac function after myocardial infarction through kynurenine. Circulation 2021; 143: 566–80. [Google Scholar]
  38. Wang Y, Song J, Yu K, et al. Indoleamine 2,3-dioxygenase 1 deletion-mediated kynurenine insufficiency inhibits pathological cardiac hypertrophy. Hypertension 2023; 80: 2099–111. [Google Scholar]
  39. Shi B, Zhang X, Song Z, et al. Targeting gut microbiota–derived kynurenine to predict and protect the remodeling of the pressure-overloaded young heart. Sci Adv 2023 ; 9 : eadg7417. [Google Scholar]
  40. Wang Q, Ding Y, Song P, et al. Tryptophan-derived 3-hydroxyanthranilic acid contributes to angiotensin II–induced abdominal aortic aneurysm formation in mice in vivo. Circulation 2017; 136: 2271–83. [Google Scholar]
  41. Metghalchi S, Vandestienne M, Haddad Y, et al. Indoleamine 2 3-dioxygenase knockout limits angiotensin II-induced aneurysm in low density lipoprotein receptor-deficient mice fed with high fat diet. PLoS One 2018; 13: e0193737. [Google Scholar]
  42. Cole JE, Astola N, Cribbs AP, et al. Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development. Proc Nat Acad Sci 2015; 112 : 13033–8. [Google Scholar]
  43. Wang Y-C, Koay YC, Pan C, et al. Indole-3-propionic acid protects against heart failure with preserved ejection fraction. Circ Res 2024; 134: 371–89. [Google Scholar]
  44. Xue H, Chen X, Yu C, et al. Gut microbially produced indole-3-propionic acid inhibits atherosclerosis by promoting reverse cholesterol transport and its deficiency is causally related to atherosclerotic cardiovascular disease. Circ Res 2022; 131: 404–20. [Google Scholar]
  45. Nunzi E, Pariano M, Costantini C, et al. Host-microbe serotonin metabolism. Trends Endocrinol Metab 2025; 36: 83–95. [Google Scholar]
  46. Mauler M, Herr N, Schoenichen C, et al. Platelet serotonin aggravates myocardial ischemia/reperfusion injury via neutrophil degranulation. Circulation 2019; 139: 918–31. [Google Scholar]
  47. Sadik A, Somarribas Patterson LF, Öztürk S, et al. il4i1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell 2020; 182: 1252–70.e34. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.